Type IV collagen as a tumour marker for colorectal liver metastases.

• About 50% of patients with primary colorectal cancer (CRC) will develop liver metastases (CLM). Currently, carcinoembryonic antigen (CEA) is the most common tumour marker for CRC and CLM. However, the sensitivity and specificity of this marker is not optimal, as almost 50% of patients have tumours that do not produce CEA. Therefore there is a need for better markers for CRC and CLM.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kirurgi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Surgery (hsv//eng)

Nyckelord

Adult

Aged

Aged

80 and over

Antineoplastic Combined Chemotherapy Protocols

pharmacology

therapeutic use

Carcinoembryonic Antigen

blood

Collagen Type IV

blood

drug effects

Colorectal Neoplasms

blood

drug therapy

pathology

Female

Fluorouracil

administration & dosage

Humans

Leucovorin

administration & dosage

Liver

metabolism

Liver Neoplasms

blood

drug therapy

pathology

secondary

Male

Middle Aged

Neoplasm Staging

Tumor Burden

Tumor Markers

Biological

blood

Collagen

Surgery

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)